Breast, Phase II
A Phase II Trial to Improve Safety of Capivasertib for HR+/HER2- Metastatic Breast Cancer
Volunteers
Health Professionals
What is the purpose of this trial?
This is a randomized, multicenter, phase II clinical trial evaluating prophylactic strategies to mitigate common toxicities associated with capivasertib in combination with fulvestrant in participants with hormone receptor-positive (HR+), HER2-negative advanced breast cancer who are eligible for this treatment regimen.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Adriana Kahn, MD
- Andrea Brennan, PA
- Armand Russo, MD
- Avery Marzulla-Dulfer, PA
- Clarice Grens, APRN
- D. Barry Boyd, MD, MS
- Diane Eannotti, APRN
- Elizabeth Gaa, APRN
- Emily Kopas, APRN, OCN
- Eric Winer, MD
- Gineesha Abraham, APRN
- Ian Krop, MD, PhD
- Jadwiga Kretowicz, APRN
- Jing Du, MD, PhD, MHS
- Johanna LaSala, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Katelyn Scott, APRN
- Kathleen Fenn, MD
- Kathryn Mason, APRN
- Lajos Pusztai, MD, DPhil
- Larisa Fleysher, APRN
- Mariya Rozenblit, MD
- Melissa Gambaccini, APRN, AOCNP, FNP-C
- Michael DiGiovanna, MD, PhD
- Michelle Corso, APRN
- Neal Fischbach, MD
- Nicole Casasanta, MD
- Rachel Iudiciani
- Sara Anastasio, APRN, RN
- Sarah Carlson, PA
- Sarah Elizabeth Schellhorn, MD
- Su Hsien Lim, MD
- Virginia Syombathy, APRN
- Wajih Kidwai, MD, FACP
- Yifei Zhang, MD
- Last Updated08/30/2026
- Study IRB#2000037614